Handok 002390.KS · KRW

Its shares trade on KRX under the ticker 002390.KS. It has been listed since 30 June 1976. In the fiscal year to 31 December 2025, it reported revenue of ₩535.14bn and a net loss of ₩2.15bn. At that date it held total assets of ₩790.75bn and shareholders' equity of ₩276.61bn.

Handok, Inc. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The firm's products include Amaryl for diabetes; Tritace for hypertension, myocardial infarction, heart failure and other cardiovascular diseases; Teveten and Triapin for essential hypertension; Munobal for hypertension and stenocardia; Ketas for disturbance of cerebral circulation; Lasix for hypertension and edema, and remedies for skin and others. The company also provides over-the-counter (OTC) pharmaceuticals, healthcare products, as well as medical devices, diagnostic reagents and vaccines. In addition, the Company is involved in the real estates rental business. On July 26, 2013, it changed its name to HANDOK Inc. from Handok Pharmaceuticals Co., LTD.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Yeong Jin KimChairman, since 2002₩943.2m
• Mr. Mi Yeon KimPresident, Director
• Mr. Jin Gi BaekCo-Chief Executive Officer, Director
• Mr. Hyeon Cheol LeeChief Financial Officer, Managing Director
• Mr. Hyeon Yik KimVice President, since 2023
• Mr. Yeong KimManaging Director
• Mr. Seung Ho BaekManaging Director
• Ms. Yun Mi KimManaging Director
• Mr. Eun Cheon LeeManaging Director
• Mr. Ju Yeon YoonManaging Director
• Mr. Dong Han KimAssistant Managing Director
• Ms. Yeong Hui GwakAssistant Managing Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.